BAX vs JAZZ: fair value comparison
Baxter International Inc. and Jazz Pharmaceuticals plc · Updated 2026-10-19
BAX currently screens as undervalued while JAZZ screens as fairly valued. Within Healthcare, BAX currently sits closer to the top of our ranking by discount to fair value. JAZZ carries the stronger quality grade.
| BAX | JAZZ | |
|---|---|---|
| Verdict | Undervalued | Fairly valued |
| Last price | $24.35 | $210.23 |
| 12-month range | $15.80–$28.35 | $131.16–$261.62 |
| Rank by discount to fair value | #40 of 108 Healthcare | #45 of 108 Healthcare |
| Quality grade | D | B |
| Leverage | High | Moderate |
| Margin trend | Contracting | Contracting |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | — | Mixed |
| DCF cross-check | — | Undervalued |
| 52-week position | The upper-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: BAX fair value analysis · JAZZ fair value analysis